Clinical Trial Update: MRD-directed Therapy for Low-risk and Intermediate-risk AML. [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial investigating MRD-directed therapy for low-risk and intermediate-risk acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Snippet

Sponsor: Nanfang Hospital, Southern Medical University | Conditions: Acute Myeloid Leukemia, Minimal Residual Disease | Phase 2, Phase 3 | Status: COMPLETED